Search results
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
InvestorPlace· 2 days agoSarepta Therapeutics (NASDAQ:SRPT) stock jumped about 30% overnight after the Food and Drug...
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Zacks via Yahoo Finance· 2 days agoFollowing the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax
The Wall Street Journal· 2 days ago**Sarepta Therapeutics (SRPT)**: Shares in the biotechnology company rocketed around 35% after the...
Sarepta Therapeutics receives expanded approval for Elevidys | Invezz
Invezz· 2 days agoSarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys ...
Sarepta Therapeutics Surges on FDA Approval for Expanded ELEVIDY
Guru Focus· 2 days agoSarepta Therapeutics (SRPT) saw a 36% surge after the FDA approved an expanded indication for ELEVIDYS. The label now includes individuals with Duchenne muscula
Why has the Sarepta stock price (SRPT) gone up more than 35%? | Invezz Why has the Sarepta stock...
Invezz· 2 days agoSarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price ...
Sarepta Therapeutics surges 36% after-hours following expanded FDA approval By Investing.com
Investing.com· 2 days agoThe drug can now be used for patients aged 4 and above who have Duchenne muscular dystrophy (DMD), a...
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval
Investor's Business Daily· 1 day agoThe gene therapy, dubbed Elevidys, already had accelerated approval for children age 4 and 5 with the muscle-wasting disease. Late Thursday, the Food and Drug Administration gave Elevidys a ...
Sarepta stock soars on Duchenne gene therapy expanded approval - Boston Business Journal
The Business Journals· 2 days agoSarepta stock (Nasdaq: SRPT) was priced at $166 per share in midmorning trading, giving Sarepta a...
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
Investopedia· 2 days agoSarepta Therapeutics (SRPT) shares soared in premarket trading Friday, a day after the Food and Drug...